Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
•
Structural Heart Disease
How do you decide between opting for semi-elective outpatient versus inpatient TAVR for patients with severe critical AS?
Related Questions
How do you decide between using a self-expanding supraannular valve and a balloon-expandable valve for TAVR in patients with severe aortic stenosis and a small aortic annulus?
Would you consider an inpatient Mitraclip for patients with severe MR and severely reduced LVEF who have been turned down/high risk for surgery if there were ongoing challenges with afterload reduction and transitioning to intermittent dialysis due to recurrent flash pulmonary edema?
What are your top takeaways from ACC 2024?
Do shorter door-to-balloon (D2B) times impact outcomes in STEMI, if it's already less than 90 minutes, and to what degree (i.e., 30 vs 60 minutes would have a more significant impact)?
Do you prefer a loading dose of 300mg or 600mg plavix for patients presenting with NSTEMI or unstable angina about to undergo LHC?
What is your preferred anticoagulation/antiplatelet regimen for younger patients presenting with ACS, found to have an acute thrombotic event requiring aspiration thrombectomy without need for stent deployment?
What is your approach in terms of surveillance, imaging modality and timing for intervention for prosthetic aortic valve insufficiency?
What could potentially account for new increases in NTproBNP or BNP levels in patients immediately post-TEER of mitral and/or tricuspid valves without clinical signs of heart failure and/or volume overload?
How long should patients with atrial fibrillation who are already on systemic anticoagulation and are status post TAVR and PCI 6 months ago remain on Plavix?
How do you approach revascularization in patients over 75 years with NSTEMI, given recent evidence from the SENIOR-RITA trial that an invasive strategy does not significantly reduce cardiovascular events compared to a conservative strategy?
